Introduction
Cerebellar atrophy is commonly identified in paediatric forms of cerebellar ataxias. This neuroradiological finding defines the childhood-onset cerebellar atrophy (ChCA) group and is generally associated with imbalance, poor coordination, developmental delay, and intellectual disability (Tavano et al., 2007; Al-Maawali et al., 2012) . This ChCA group includes a large number of clinically heterogeneous genetic diseases frequently comprising epilepsy. Molecular diagnosis is challenging, as an ever-increasing number of very rare conditions are associated with ChCA. Importantly, such cerebellar atrophies are present in a group of progressive, severe diseases with key diagnostic features that can appear several years after initial patient assessment (Gregory et al., 2008; Fusco et al., 2013; Romani et al., 2015) and with a critical need of early diagnosis. Next generation sequencing including whole exome sequencing (WES) has accelerated molecular diagnosis and improved patient management (Sawyer et al., 2014; Deciphering Developmental Disorders Study, 2015; Megahed et al., 2016) . These approaches have identified a high prevalence of damaging de novo mutations with dominant effect in common developmental disorders such as intellectual disability, autism spectrum disorders and epilepsy (Deciphering Developmental Disorders Study, 2017) . A mean prevalence of 1 in 295 births (42% of the affected individuals) was estimated for monoallelic developmental disorders caused by de novo mutations. Understanding if these de novo events act through loss or gain of function effect can be important for treatment consideration (Boycott et al., 2013) . About half of de novo mutations alter protein function through gain of function or dominant negative effects (Deciphering Developmental Disorders Study, 2017) . Gain-of-function mutations that are associated with the ectopic or increased activation of specific protein or pathway allow the identification of define targets used for the drug design (Segalat, 2007) . In contrast small molecule drug development for loss-of-function mutations is especially challenging (Yue, 2016) . Consequently, the identification of de novo, gain-of-function mutations could benefit both molecular diagnosis and treatment development.
The prevalence of de novo mutations has been documented in large cohorts (Deciphering Developmental Disorders Study, 2017) but such studies often include a wide range of heterogeneous conditions with limited clinical data. Among these conditions, brain structural defects including microcephaly, diffuse cortical brain malformations or ChCA are classically associated with recessive inheritance (Al-Maawali et al., 2012; Sawyer et al., 2014; Desikan and Barkovich, 2016; Cavallin et al., 2017) . More recently, de novo mutations in several genes have been reported in ChCA (Gerber et al., 2016; Travaglini et al., 2017; Watson et al., 2017; Kurihara et al., 2018) . However, the extent of the contribution of these rare de novo events to the genetic basis of ChCA is not known.
To estimate the prevalence of de novo versus inherited mutations in ChCA, we investigated a cohort of 47 patients with ChCA and/or hypoplasia using a custom targeted next generation sequencing gene panel (TNGS) and WES. This investigation led us to identify pathogenic de novo events as the major cause of ChCA. Additional exploration of candidate de novo mutations identified CACNA1G as a new ChCA gene with a gain of function effect as the disease mechanism.
Materials and methods

Subject information
The 47 patients included in this study are from the 37 families and were referred to the departments of paediatric neurology, genetics, metabolism or ophthalmology of the Necker Enfants Malades Hospital. This cohort includes 25 female and 22 male subjects. Consanguinity of the parents was documented for six families (16.2%) and 10 families (27%) include two affected siblings. Patients were recruited upon the clinical findings of cognitive and motor impairment during paediatric age including cerebellar signs such as oculomotor abnormalities, truncal ataxia and head movements and the presence of cerebellar atrophy and/or hypoplasia on MRI. Patients with both atrophy and hypoplasia are included as these conditions are not always distinguishable (Poretti et al., 2008) . Both static and progressive conditions were included. This cohort includes 15 families with pons involvement (40.5%). The MRI examination consisted of sagittal spin echo T 1 , axial fast spin echo T 2 and coronal fluid-attenuated inversion recovery (FLAIR) images. In the absence of sequential scans, cerebellar atrophy was diagnosed with the identification on MRI of shrunken folia and large cerebellar fissures. High-resolution karyotype, array-comparative genomic hybridization (CGH) (400 kb resolution) was performed. Informed consents have been obtained both from the participants and the legal representatives of the children.
Targeted gene panel and whole exome sequencing TNGS was prioritized unless the clinical presentation suggested a new syndromic entity that was directly explored through WES. Patients negative with TNGS were explored with WES to identify new disease gene. Patients primarily tested negative with WES were also analysed with TNGS to rule out mosaic mutations or small copy number variations (de Ligt et al., 2013; Hayashi et al., 2017) .
A custom gene panel including 72 ChCA genes (Supplementary Table 1 ) was set up for this study.
Cerebellar hypoplasia genes were included as this phenotype often overlaps with cerebellar atrophy at the paediatric age (Poretti et al., 2014) . Genes such as CASK, EXOSC3 or WDR81 can be involved in cerebellar atrophy/hypoplasia without or with pons hypoplasia [i.e. pontocerebellar hypoplasia (PCH)] and consequently PCH genes are also included. Genomic DNA libraries were generated from 2 mg DNA sheared with a Covaris S2 Ultrasonicator using SureSelectXT Library PrepKit (Agilent) and the Ovation Õ Ultralow System V2 (NuGen) according to the suppliers' recommendations. 1459 regions of interest encompassing all exons and 25 base pairs intronic flanking sequences of the 72 selected genes were captured by hybridization with biotinylated complementary 120-bp RNA baits designed with SureSelect SureDesign software (hg19, GRCh37, February 2009). The 309.16 kb targeted DNA region was pulled out with magnetic streptavidin beads, PCR-amplified using indexing primers and sequenced on an Illumina HiSeq2500 HT system. NGS data analysis was performed with Paris Descartes University/Institut IMAGINE's Bioinformatics core facilities. Paired-end sequences were mapped on the human genome reference (NCBI build37/ hg19 version) using the Burrows-Wheeler Aligner. Downstream processing was carried out with the Genome Analysis Toolkit (GATK), SAMtools, and Picard, according to documented best practices (http://www.broadinstitute.org/ gatk/guide/topic?name=best-practices). WES was performed with DNA extracted from blood and processed at the Genomic core facility in the Imagine Institute as previously described (Megahed et al., 2016) . A WES trio approach (i.e. sequencing of DNA from the mother, father and the affected child) was performed for 24 families. Briefly, exome capture was performed with the SureSelect Human All Exon kit (Agilent technologies) and sequencing was carried out on a HiSeq2500 (Illumina). The mean depth of coverage obtained for each sample was 4150Â with 497% of the exome covered at least 30Â.
All identified variants were validated using Sanger sequencing or multiplex ligation-dependent probe amplification (MLPA) for duplications or deletions.
Identification of additional patients with neurodevelopmental disorders and de novo CACNA1G mutations was possible through collaborations. Subject 2 was identified at the Children's Hospital CHU of Dijon that sequenced $650 clinical exomes from patients with neurodevelopmental defects (Bourchany et al., 2017) . Subjects 3 and 4 were identified through GeneMatcher web site (Sobreira et al., 2015) and sequenced by the GeneDx laboratory (Kü ry et al., 2017) .
Variant analysis, databases and bioinformatic tools
A variant filtering pipeline was systematically applied to narrow down the number of putative causative variants. All the possible inheritance patterns were tested. Briefly, variant calling was performed with the GATK Unified Genotyper (https://www.broadinstitute.org/ gatk/) based on the 72 version of ENSEMBL database. Common variants (i.e. minor allele frequency 41%) were filtered out by using dbSNP, 1000 Genomes databases and our In-house exome collection, which includes more than 10 000 exomes. Further, functional (protein-altering) alleles were prioritized versus non-functional. Tables 2 and 3) include genes with variants identified in at least two unrelated families with similar clinical phenotype but not previously reported. Ca v 3.1 protein structure modelling was performed using the RaptorX web server (Kallberg et al., 2012) , based on Ca v 1.1 structure (Wu et al., 2015) .
Site directed mutagenesis, cell culture and transfection protocols Site-directed mutagenesis of the human wild-type Ca v 3.1 encoding plasmid (canonical transcript NM_018896.4 cloned into pcDNA3.1) was performed using the QuikChange sitedirected mutagenesis kit (Agilent Technologies) to introduce the A961T and M1531V CACNA1G mutations. Mutations were verified by Sanger sequencing of the full coding sequence. HEK-293T cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with GlutaMax TM , 10% foetal bovine serum and 1% penicillin/streptomycin (Invitrogen). Transfections were performed using jet-PEI (QBiogen) with a DNA mix (1.5 mg total) containing 0.5% of a GFP-encoding plasmid and 99.5% of either of the plasmids that code for the human Ca v 3.1 wild-type, Ca v 3.1 A961T and Ca v 3.1 M1531V constructs. Two days after transfection, HEK-293T cells were split using Versene (Invitrogen) and plated at a density of $35 Â 10 3 cells per 35 mm Petri dish for electrophysiological recordings, which were performed the following day.
Electrophysiological recordings
Macroscopic T-type Ca 2 + currents were recorded at room temperature using an Axopatch 200B amplifier (Molecular Devices). Borosilicate glass pipettes had a resistance of 1.5-2.5 MV when filled with an internal solution containing (in mM): 140 CsCl, 10 EGTA, 10 HEPES, 3 Mg-ATP, 0.6 Na-GTP, and 3 CaCl 2 (pH adjusted to 7.25 with KOH, $315 mOsm). The extracellular solution contained (in mM): 135 NaCl, 20 TEACl, 2 CaCl 2 , 1 MgCl 2 , and 10 HEPES (pH adjusted to 7.25 with KOH, $330 mOsm). Recordings were filtered at 2 kHz. In some experiments, TTA-P2 (Alomone) was applied using a gravity-driven homemade perfusion device (100 ml/min) and control experiments were performed similarly using the vehicle alone. Data were analysed using pCLAMP9 (Molecular Devices) and GraphPad Prism (GraphPad) software. Results are presented as the mean AE standard error of the mean (SEM), and n is the number of cells. Statistical analyses were performed with the Student t-test or with oneway ANOVA combined with a Tukey post-test for multiple comparisons (*P 5 0.05, **P 5 0.01, ***P 5 0.001).
Cerebellar nuclear neuron modelling
Modelling was performed using the NEURON simulation environment (Hines and Carnevale, 1997) . The model of cerebellar nuclear neuron is based on a previously published model [Sudhakar et al., 2015 ; downloaded from the model database at Yale University (https://senselab.med.yale.edu/modeldb/)]. We generated neuronal activities using medium value of input gain, as described in Figure 1B in Sudhakar et al. (2015) . The electrophysiological properties of the Ca v 3.1 channels were modelled using Hodgkin-Huxley equations as described previously (Huguenard and Prince, 1992; Destexhe et al., 1996) . The values obtained for the Ca v 3.1 wild-type, A961T and M1531V mutants were substituted for the corresponding values of native T-channels in cerebellar nuclear neurons. The membrane voltage values were corrected for liquid junction potential, which was 4.5 mV in our recording conditions. The equations to model the Ca v 3.1 wild-type current properties were: The equations to model the Ca v 3.1 A961T current properties were: The equations to model the Ca v 3.1 M1531V current properties were:
Results
Combined custom gene panel and exome sequencing identify de novo mutations as a prevalent cause of ChCA
To identify the molecular causes of ChCA, we investigated a cohort of 47 patients with ChCA and/or hypoplasia using a combination of custom TNGS and WES. With mean target coverage of 430 Â (99.9% of targeted DNA covered more than 30Â), the TNGS was used as a primary test for most of the families and identified likely diagnosis for 7 of 25 families sequenced (28%; Supplementary Tables 1 and  2 ) including heterozygous insertions and deletions (n = 4) poorly or not detected by WES and CGH array analysis. WES identified likely causative variants in known ChCA genes for 6 of 32 families tested and the combination of these approaches was able to identify confident causative variants for 35% of families (Fig. 1A ). All these variants are located in genes previously associated with comparable clinical phenotypes. They are inherited through an autosomal recessive mode (13% of the families; n = 5) or arise de novo (22% of the families; n = 8) as either X-linked or autosomal dominant. Most of the cases of de novo mutations involve the CASK (calcium/calmodulin dependent serine protein kinase) gene, including a male patient with a truncating germ line de novo mutation and spared pontine bulging on MRI (Fig. 1B) . A recurrent de novo variant was also identified in the recently reported CTBP1 (C-terminal-binding protein 1) gene (Beck et al., 2016) in a patient with non-progressive cerebellar atrophy (Fig. 1C ) but without the previously-described tooth enamel defects. To assess the prevalence of de novo events in the remaining undiagnosed patients, we explored the WES data for de novo and recessive variants located in genes not previously associated with ChCA. Using strict variant frequency criteria (see 'Materials and methods' section), we identified five index cases with de novo variants and five others with recessive variants (Fig. 1A) . Four of the de novo variants are located in highly constrained genes (loss-of-function intolerance P LI = 1; Supplementary Table 3) as expected for causative de novo mutations (Samocha et al., 2014) . Ten females and three males carry validated and probably causative de novo variants. A probably causative variant was identified for 62% of the families (n = 23) with a molecular finding, which supports the idea that de novo mutations are prevalent in ChCA. To unravel how these de novo mutations can affect the developing cerebellum integrity, we focused on a variant located in the CACNA1G gene, the gene encoding the Ca v 3.1 T-type calcium channel. Ca v 3.1 channel is highly expressed in Purkinje neurons and deep cerebellar nuclei, where it plays an important role in signal processing and synaptic plasticity (Isope et al., 2012; Ly et al., 2013) . However, evidence supporting its involvement in human cerebral development is lacking.
De novo variants in the CACNA1G gene are associated with severe congenital encephalopathy WES analysis on Subject 1 and her parents (Family CerID08) did not identify recessive variant that could have explained the cerebellar syndrome but identified a Sanger-validated de novo variant in the CACNA1G gene predicting a p.Ala961Thr alteration as the only diseasecausing variant. By using a collaborative network and the GeneMatcher platform, we followed a genotype-first approach and identified three additional cases with confirmed de novo mutation in the CACNA1G gene. These cases were subsequently included in this study for clinical comparison and functional investigation. WES analysis performed in these additional cases identified the same p.Ala961Thr missense change in Subjects 3 and 4, suggesting a hotspot mutation, while Subject 2 harbours a p.Met1531Val alteration (see Supplementary material). These four patients were born after a full-term pregnancy. Epileptic encephalopathy was first detected for Subjects 2 and 3 in the first 2 weeks of life but seizures were not present in the two others. All the subjects presented between birth and 1 year of age with global developmental delay, axial hypotonia, and peripheral hypertonia. As early as 8 months of age, cerebellar symptoms were detected and associated with global cerebellar atrophy seen on MRI ( Fig.  2A-J) . Motor and cognitive developments were very limited as patients could not stand or walk without aid and patients were described as either non-verbal or with very limited language development. Microcephaly was detected in two patients. Facial dysmorphisms and digital anomalies were present including abnormal hairline, short hands and feet, broad thumbs and great toes [ Fig. 2K -O, Table 1 and Supplementary material (case reports)]. The identified de novo variants involve two amino acids fully conserved at the protein level (Fig. 2P ). In addition, these variants are absent from the ExAC database and predicted to be deleterious by PolyPhen-2, SIFT, and MutationTaster. The four subjects have comparable clinical signs including cognitive developmental defects and cerebellar ataxia. Based on this observation, in combination with the predicted deleterious impact of the variants, we hypothesized that p.Ala961Thr and p.Met1531Val alterations are responsible for the congenital encephalopathy present in these patients.
ChCA mutants display currents with slow kinetics and activate and inactivate at negative membrane potentials Both A961 and M1531 amino acids are located at the inner part of the S6 segments of the domains II and III of the Ca v 3.1 protein, respectively, the S6 segments contributing to the pore lining of the channel (Fig. 2Q-S) . We therefore investigated the electrophysiological impact of the A961T and M1531V mutations. It is worth noting that these mutations were introduced in the Ca v 3.1a channel isoform, which is highly expressed in the human cerebellum (Monteil et al., 2000) . The Ca v 3.1 channels, wild-type and mutants (A961T and M1531V) were expressed in HEK-293T cells and the T-type Ca 2 + current was measured in the whole-cell configuration of the patch-clamp technique. As presented in Fig. 3 , all the Ca v 3.1 constructs generated robust low voltage-activated currents with a peak current near À35/À40 mV (Fig. 3A) . The current density was unchanged in cells expressing A961T and M1531V mutant channels, compared to cells expressing wild-type channels ( Table 2 ). The A961T and the M1531V currents activated at more negative potentials as compared to the wild-type Ca v 3.1 current (Fig. 3A and B) . We found that the potential for half-activation (V 1/2 ) was significantly shifted by $À6 mV and by $À11 mV for the A961T and the M1531V mutants, respectively (Table 2) . Importantly, both mutants displayed currents with markedly slow inactivation kinetics at all test pulse potentials ( Fig. 3A and C) . As shown in Table 2 , the A961T mutant exhibited on average $5 times slower inactivation kinetics than the wild-type channel whereas the inactivation kinetics of the M1531V mutant was $3 times slower. Similarly, the deactivation kinetics of both mutants was $3/5 times slower than those of wild-type channels (Fig. 3D and Table 2 ). We next investigated the steady state inactivation properties of the Ca v 3.1 mutants by stepping holding potentials from À130 mV to À40 mV (Fig. 4A) . Both A961T and M1531V currents showed a potential for half-inactivation (V 1/2 ) that was shifted by $12 mV toward negative potentials (Fig. 4A , B and Table 2 ). In addition, the recovery from inactivation of the A961T current, but not of the M1531V current, was markedly slower than the recovery from inactivation of the wild-type channels ( Fig. 4C and D) . Notably, the A961T current did not entirely recover after an interpulse as long as 15 s (Fig. 4D) . Overall, these experiments have revealed striking changes in the electrophysiological properties for A961T and M1531V mutant channels likely supporting gain of channel activity.
The A961T and the M1531V Ca v 3.1 mutants increase neuronal firing in a deep cerebellar nucleus neuron model
To elucidate whether the A961T and M1531V mutants would correspond to gain-of-function mutations and promote increased excitability in cerebellar neurons, we performed simulation experiments. These experiments were carried out using an established computational model of the neuronal activities in deep cerebellar nucleus neuron (Steuber et al., 2011; Sudhakar et al., 2015) , in which the electrophysiological parameters of A961T and M1531V mutants were computed and compared to the wild-type Ca v 3.1 channel condition for their ability to modulate firing activity (Fig. 5) . Turning off the T-type channel conductance in this model resulted in a decrease in spike frequency ( Fig. 5A and B) . Importantly, substituting the wildtype Ca v 3.1 channel parameters with those of the two mutants, especially A961T, markedly increased the spike frequency. The spike frequency was 44 Hz with the wild-type ( Fig. 5A and E) channel whereas it reached 54 Hz (4 22%) with the M1531V mutant ( Fig. 5D and E) and 88 Hz (4100%) with the A961T mutant ( Fig. 5C and E) . These data support that the A961T and M1531V are gain-offunction mutations, promoting increased firing activity in deep cerebellar nucleus neurons.
The A961T and the M1531V Ca v 3.1 mutants generate a large window current fully blocked by TTA-P2
Collectively, the changes in T-type channel gating for the A961T and M1531V mutants are expected to support larger Ca 2 + influx at membrane potentials close to the cell's resting potential. In addition, these mutant channels that remain open longer upon depolarization would allow further increase in the Ca 2 + entry. Our electrophysiological data are predictive of a T-type window current (a persistent background calcium current) that would be larger for the A961T and M1531V mutants than the one generated by wild-type channels. To test this hypothesis, we first performed long-lasting recordings at À70 mV (Fig. 6A-D) . We found that the wild-type channel displayed a fast inactivating current with no detectable current measured after 5 s (Fig. 6A) . In contrast, a significant fraction of the calcium current was persistent for the A961T (Fig. 6B ) and M1531V mutants (Fig.  6C) . On average, this persistent current represented only $0.33% of the maximal current for the wild-type channel (n = 5) whereas it reached $2.5% of the maximal current for the A961T mutant (P 5 0.05; n = 8), and $3.8% of the maximal current for the M1531V mutant (P 5 0.01; n = 10; Fig. 6D ). We next performed ultra-slow depolarizing voltage ramps (10-s duration) to record directly the window current over a large range of membrane potentials (Fig. 6E-G) . The Ca v 3.1 wild-type generated a window current of small amplitude, whereas both the A961T and the M1531V mutants produced a window current of significantly much larger amplitude ( Fig. 6E-G, left panels) . To analyse the window current, the ratio of the window current amplitude over the maximal current obtained in the same cell using a standard pulse protocol was quantified (Fig. 6H) . On average we found that the window current represented about 1% of the total current for the wild-type channel (n = 6), while it was significantly larger for the A961T mutant ($11%; P 5 0.01, n = 6) and the M1531V mutant ($8%; P 5 0.01, n = 6). In addition, in the presence of TTA-P2 (5 mM), a selective T-type channel blocker that penetrates well the CNS (Shipe et al., 2008) and blocks the native T-type currents in deep cerebellar nuclear neurons (Boehme et al., 2011) , the window current was completely abolished both for wild-type and mutant Ca v 3.1 channels (Fig. 6H) . Furthermore, concentration-response curves for TTA-P2 (Fig. 6I ) indicated similar inhibition of wild-type (IC 50 = 0.16 AE 0.02 mM, n = 7), A961T (IC 50 = 0.14 AE 0.03 mM, n = 5) and M1531V Ca v 3.1 channels (IC 50 = 0.24 AE 0.05 mM, n = 6). Importantly, TTA-P2 used at micromolar concentrations is known to have no inhibitory effect on sodium and high-voltage activated calcium channels, including Ca v 2.3 (Choe et al., 2011) .
Discussion
Based on the exploration of a cohort of 47 children, our study provides several novel and important findings documenting the aetiology of ChCA. First, using a combination of a gene panel and WES, we identified causative and likely causative variants in previously reported genes as well as novel candidate genes. Overall, de novo mutations appear to be more prevalent than recessive mutations in ChCA. Second, further investigation of a de novo variant in the CACNA1G gene, in collaboration with other groups, led to the discovery of three additional cases with recurrent or clustered de novo variants and comparable clinical phenotype. Third, our electrophysiological study of these .1 wild-type (n = 4), Ca v 3.1 A961T (n = 10) and Ca v 3.1 M1531V (n = 6) currents. Deactivation (tail) current were generated by a short (4 ms) test pulse at À30 mV followed by repolarization potentials ranging from À120 mV to À60 mV. Average values and statistical analysis can be found in Table 2 . Table 2 Electrophysiological properties of the A961T and M1531V mutants of Ca v 3.1 channels CACNA1G mutations provided evidence for a gain of activity of the mutant Ca v 3.1 channels causing hyperexcitability in deep cerebellar neurons. Here we describe a comparable incidence of likely causative de novo mutations in our cohort of ChCA cases compared to the whole group of developmental disorders, 35% versus 42%, respectively (Deciphering Developmental Disorders Study, 2017). As previously reported in studies of cohorts with de novo mutations, we also observed an unexplained higher incidence in females versus males, a variable expression of epilepsy phenotype seen in patients with mutations in epilepsy/seizure-associated genes and the clustering of characterized gain-of-function mutations (Deciphering Developmental Disorders Study, 2017; Geisheker et al., 2017) . Alteration of calcium homeostasis and signalling is one of the recurrent causes of ataxia and neurodegeneration (Tomlinson et al., 2009; Matilla-Duenas et al., 2014; Coutelier et al., 2017) . In addition to CACNA1G, mutations in other genes involved in intracellular calcium signalling (ITPR1; Tada et al., 2016) or regulated by intracellular calcium (CASK; Lu et al., 2003) were also identified in our screen, further supporting the relevance of calcium homeostasis alteration in the context of ChCA.
This study is the first report characterizing de novo gainof-function mutations in CACNA1G associated with a congenital disorder. Based on the phenotype in four children with mutations exhibiting strong Ca v 3.1 dysfunction, we could delineate a novel calcium channelopathy condition that includes severe psychomotor retardation, cerebellar ataxia, digital anomalies and variable facial dysmorphisms, as well as features with incomplete penetrance such as microcephaly and epilepsy.
Our study adds to previous genetic and functional investigations of de novo gain of function mutations in other voltage-gated calcium channel genes. Timothy syndrome is a multi-systemic disorder with developmental delay, autism spectrum disorder, facial dysmorphism, cardiac arrhythmia (long QT syndrome) and syndactyly as the core features (Splawski et al., 2004 (Splawski et al., , 2005 . It results from gain of function mutations in the CACNA1C gene, which codes for the L-type Ca v 1.2 calcium channel. Recently, investigation of patients with primary aldosteronism led to the identification of de novo mutations in the CACNA1H (Scholl et al., 2015; Daniil et al., 2016) and CACNA1D (Scholl et al., 2013) genes coding, respectively, for the T-type Ca v 3.2 and the L-type Ca v 1.3 calcium channels. Other CACNA1D wild-type (top, black traces) and a cell expressing Ca v 3.1 A961T (bottom, red traces). Recovery from inactivation was measured using a two-pulse protocol at À30 mV separated by an interpulse at À100 mV whose duration ranged from 10 ms to 15 s. (D) Recovery from inactivation of Ca v 3.1 wild-type (black, n = 7), Ca v 3.1 A961T (red, n = 7) and M1531V currents (blue, n = 6). Note that recovery from inactivation of Ca v 3.1 A961T mutant channels was best fitted with a two-exponential function, contrary to the recovery from inactivation of wild-type and M1531V channels (Table 2) .
mutations with consequences on the cognitive development were also reported (Pinggera et al., 2015) . Collectively, these studies highlight the broad role of calcium and voltage-gated calcium channels in the development and/or functioning of the heart, adrenal cortex and brain, among others, and that altered calcium signalling can give rise to a variety of cellular and organ defects exemplified in the human calcium channelopathies previously described.
It is likely that the full clinical spectrum associated with CACNA1G mutations is incomplete. Monoallelic deletions of the CACNA1G gene have been associated with mild intellectual disability without cerebellum atrophy (Preiksaitiene et al., 2012; Bardai et al., 2016; Jewell et al., 2017) . The significant difference with the neurological phenotype associated with A961T and M1531V CACNA1G variants is consistent with a gain-of-function effect for these mutations. A CACNA1G de novo variant of unknown pathogenicity and associated with autism, mild intellectual disability and dyspraxia was previously reported (Deciphering Developmental Disorders Study, 2015) . Interestingly, a recurrent and inherited mutation in CACNA1G was described in patients with late-onset cerebellar ataxia (Coutelier et al., 2015; Morino et al., 2015) . This R1715H mutation is located in the S4 of domain IV and exhibits a modest but significant effect on the electrophysiological properties (Coutelier et al., 2015) . In this context, the cognitive function of the patients was generally described as normal contrasting with the severely impaired cognitive development of the patients with de novo CACNA1G mutations. The role of the cerebellum in the cognitive function and especially in Typical calcium current recorded in response to a 5-s test pulse at À70 mV (dark traces), for Ca v 3.1 wild-type (A), A961T (B) and M1531V (C) channels. The light traces correspond to the 5-s test pulse at À100 mV. (D) Average normalized persistent current amplitude. For each cell, the current was measured after 5 s at À70 mV and was normalized to the maximal current recorded using standard I-V curve protocol [Ca v 3.1 wildtype (n = 5), Ca v 3.1 A961T (n = 8) and Ca v 3.1 M1531V (n = 10) channels]. (E-G) Window currents were elicited using very slow (10 s) voltageramps from À100 mV to 0 mV in the absence (left) and in the presence of 5 mM TTA-P2 (right) for Ca v 3.1 wild-type (E), A961T (F) and M1531V (G) channels. (H) Average normalized window current amplitude. For each cell, the window current was normalized to the maximal current recorded using standard I-V curve protocol and averaged for each condition [Ca v 3.1 wild-type (n = 6), Ca v 3.1 A961T (n = 6) and Ca v 3.1 M1531V (n = 6) channels] before (filled bars) and after application of 5 mM TTA-P2 (open bars), a selective T-type calcium channel blocker. (I) Concentrationresponse curves of TTA-P2 for wild-type (n = 7), A961T (n = 5) and M1531V (n = 6) Ca v 3.1 channels. The dose dependence of the current inhibition by TTA-P2 was fitted with the sigmoidal Hill equation. Currents were elicited at À30 mV from a holding potential of À90 mV at a frequency of 0.1 Hz. Ctrl = control; WT = wild-type.
children's learning is recognized although not well understood (Tavano et al., 2007; Steinlin, 2008) . Considering the prevalent expression of CACNA1G in the cerebellum, it is tempting to speculate that a disrupted cerebellar development caused by severe CACNA1G mutations could be mainly responsible for cognitive impairment, supporting a critical role of the cerebellum in cognitive development.
Our patch-clamp experiments clearly document that A961T and M1531V CACNA1G mutations strikingly alter the electrophysiological behaviour of Ca v 3.1 channels, especially the fast inactivation property, which is one of the most distinctive features of these channels. Both inactivation and deactivation kinetics were significantly slowed for the mutated channels. Both steady state activation and inactivation properties were affected with the potentials for half-inactivation and for half-activation significantly shifted toward negative potentials. On the one hand, slowing of inactivation and deactivation kinetics would correspond to a gain of channel activity, allowing larger entry of calcium into the cell. On the other hand, a negative shift in the steady state inactivation would be consistent with a loss of channel activity as a smaller fraction of Ca v 3.1 channels would activate in the physiological range of the membrane potential. Modelling experiments were therefore instrumental to demonstrate that both A961T and M1531V could enhance firing activity in deep cerebellar nucleus neurons and, consequently, to validate that these two mutations are gain-of-function mutations.
The A961 and M1531 amino acids are located in the intracellular part of the S6 segment in domains II and III, respectively. In good agreement with the hypothesis that clustering of de novo missense variants help identify functional protein domains (Geisheker et al., 2017) , we show here the close 3D proximity of the A961 and M1531 residues in the Ca v 3.1 protein. The M1531 residue is part of a Met-Phe-Val (MFV) sequence of the IIIS6 segment, which was implicated in Ca v 3.1 channel inactivation in early structure-function studies (Marksteiner et al., 2001; Talavera and Nilius, 2006) . The study by Marksteiner et al. (2001) , in which M1531 corresponds to M1501 in the rat cDNA, described that the mutants showing a delayed inactivation also showed a slower recovery from inactivation. Interestingly, the recurrent mutation in CACNA1H (Ca v 3.2) described at position M1549 with two distinct substitutions, M1549V (Scholl et al., 2015) and M1549I (Daniil et al., 2016) is also part of the highly conserved MFV sequence in IIIS6 segment of Ca v 3 channels. Similar to the M1531V-Ca v 3.1 described here, M1549V and M1549I mutations profoundly alter the electrophysiological properties of the Ca v 3.2 current, exhibiting a significant hyperpolarization shift in activation and inactivation properties, a significant slowing of the activation, inactivation and deactivation kinetics with an expected increase in calcium entry and aldosterone production (Daniil et al., 2016) . Combined together, these studies establish this conserved methionine residue in IIIS6 as a major determinant for T-type channel inactivation.
By describing marked effects of the A961T mutation on the inactivation properties, our study demonstrates that both the S6 segments of domains II and III contribute to the inactivation gate of the Ca v 3.1 channel pore. To the best of our knowledge, a role in inactivation of this conserved Alanine residue in IIS6 is not yet documented, but surrounding residues, especially V960 and I962, were reported for their implication in Ca v 3.2 inactivation (DemersGiroux et al., 2013) . When expressed in Xenopus oocytes, the Ca v 3.2 mutants V1011G and I1013G, but not A1012G, showed significantly slower activation, deactivation and inactivation kinetics (Demers-Giroux et al., 2013) . This VAI sequence in IIS6 segment, highly conserved in Ca v 3 channels, may correspond to the MFV locus in IIIS6, being also a critical determinant in T-type channel inactivation.
Remarkably, other de novo mutations in voltage-gated calcium channels 1 paralogues share similitudes in their location and functional consequences. The two original mutations identified in Timothy syndrome, G406R and G402S are located at the boundary between the S6 segment of domain I (IS6) and the I-II loop in the Ca v 1.2 protein. These mutations markedly slow inactivation kinetics of the L-type current leading to a net increase in calcium influx and a prolonged cardiac action potential (Splawski et al., 2004 (Splawski et al., , 2005 Bidaud and Lory, 2011) . A similarly localized de novo mutation (G407R) was recently found in CACNA1D, the gene encoding the L-type Ca v 1.3 calcium channel. It was associated with pronounced slowing of current inactivation as well as a negative shift in the steady state activation and inactivation (Pinggera et al., 2015) . All together, these data highlight the physiological importance of the intracellular part of the S6 segments as a hotspot for de novo gain-of-function mutations in the Ca v channel family. These cross-paralogue similarities should stimulate further investigations of de novo variants in other protein families and facilitate the identification of gain-of-function mutations.
Identifying a gain of channel activity for ChCA mutants of the T-type Ca v 3.1 channel may represent a clue to design a therapeutic strategy, as T-type channel blockers exist. Interestingly, both A961T and M1531V mutant channels generate an aberrantly elevated window current. The T-type window current allows a permanent entry of calcium ions at physiological cell's resting membrane potentials and any elevated window current would disrupt intracellular calcium homeostasis, thus contributing to the pathological effects. Expectedly, we found that the window current was fully inhibited by TTA-P2, a selective T-type channel blocker (Shipe et al., 2008; Dreyfus et al., 2010) . It is tempting to speculate that TTA-P2 could be a useful drug to treat T-type dependent cerebellar atrophy. Preclinical studies in dogs and rats have shown that an oral dose of 10 mg/kg TTA-P2 could lead to micromolar plasma concentration. TTA-P2 penetrates well the CNS as it blocks tremor activity induced by harmaline without cardiac and renal deleterious side effects (Shipe et al., 2008) .
Compounds selective on T-type channels are expected to have therapeutic utility to treat neurological disorders in which Ca v 3 channels are upregulated, including neuropathic pain and epilepsy (Zamponi, 2016) . Further studies are now necessary to establish the precise therapeutic potential of T-type calcium channel blockers in ChCA.
